Clinical Trials Logo

Filter by:
NCT ID: NCT05734989 Not yet recruiting - Type 2 Diabetes Clinical Trials

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

Start date: April 2024
Phase:
Study type: Observational

In this study, the investigators will utilize community organizations to screen Hispanics/Latino(a)s for kidney disease, diabetes, and other risk factors, and refer them for care with a PCP. Additionally, the investigators will implement an intervention in local health clinics to assist PCPs with screening and treating patients with diabetes. Completion of the project will hopefully slow progression of kidney disease among Hispanic/Latino(a) patients in Durham, and the information gained will allow the investigators to eventually perform the intervention on a larger scale.

NCT ID: NCT05745740 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Start date: April 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.

NCT ID: NCT05766241 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorder

Investigating a Novel Sensory-based Program for Veterans With PTSD

SENSE-PTSD
Start date: April 2024
Phase: N/A
Study type: Interventional

SENSE-PTSD is an randomized controlled trial (RCT) which will evaluate the feasibility and efficacy of a novel, sensory-based psychoeducational program for improving psychological, functional, sensory, and cognitive outcomes in Canadian military veterans with posttraumatic stress disorder (PTSD).

NCT ID: NCT05769491 Not yet recruiting - Breast Cancer Clinical Trials

Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Start date: April 2024
Phase:
Study type: Observational

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in Triple Negative Breast Cancer clinical trials, as well as the reasons for withdrawal or discontinuation. The insights gained from this study will ultimately benefit those with Triple Negative Breast Cancer who may be invited to participate in clinical research in the years to come.

NCT ID: NCT05769504 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Examining Clinical Trial Participation for Small Cell Lung Cancer Patients

Start date: April 2024
Phase:
Study type: Observational

Clinical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.

NCT ID: NCT05776316 Not yet recruiting - Substance Abuse Clinical Trials

Harm Reduction Services

HRS
Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).

NCT ID: NCT05776628 Not yet recruiting - Clinical trials for Herniated Disk Lumbar

Evaluation of Plenum® Tissue Ortho to Prevent Epidural Fibrosis and Post-laminectomy Syndrome.

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare if adding a polydioxanone membrane prevents epidural fibrosis and, consequently, the rate of occurrence of the post-laminectomy syndrome in participants undergoing microdiscectomy for treatment of disc herniation.

NCT ID: NCT05778045 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences

Start date: April 2024
Phase:
Study type: Observational

Medical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. Participating in an observational clinical trial may help patients with non-small cell lung cancer since it advances medical knowledge and may improve treatment choices in the future.

NCT ID: NCT05779930 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma. Patients will undergo screening, leukapheresis (cell collection), lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by the anti-CD19 CAR T cell infusion. The lymphodepleting chemotherapy is administered over four days IV to prepare the body for the CAR T cells. The anti-CD19 CAR-T cells are infused between 2-14 days after the last dose of chemotherapy. This study is designed for participants to begin lymphodepleting chemotherapy during the CAR T cell manufacture and receive a fresh cell infusion on the day that manufacturing is complete. Some patients may need more time in between the cell collection and the CAR T cell infusion, therefore, the cells may be manufactured and frozen prior to administration. Patients will be followed for a year after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy.

NCT ID: NCT05782491 Not yet recruiting - Cardiogenic Shock Clinical Trials

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Start date: April 2024
Phase: N/A
Study type: Interventional

The Abiomed Impella 5.5 is a surgically placed temporary mechanical support device used in patients in cardiogenic shock. The investigators propose using regional anesthesia (3 separate peripheral nerve blocks) to facilitate Impella 5.5 placement, a procedure which has traditionally been performed under a general anesthetic. Regional anesthesia is a proven and widely used technique to facilitate upper extremity vascular surgery cases (i.e. arteriovenous fistula creation). The investigators believe that employing these blocks in conjunction with intravenous sedation or monitored anesthesia care (MAC anesthesia) - a technique used in all types of cases, even in sick hearts during thranscatheter aortic valve replacements (TAVR) - will avoid the need increased doses of medications to support the blood pressure and cardiac output, avoid the need for post operative mechanical ventilation and intravenous sedation, and speed up the time to participating in physical therapy, time to heart transplant/durable mechanical support/recovery, and time to hospital discharge.